A Phase IIA Multicenter Evaluation of the Safety and Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Patients With Relapsed Stage IIIB OR IV Non Small Cell Lung Cancer

Trial Profile

A Phase IIA Multicenter Evaluation of the Safety and Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Patients With Relapsed Stage IIIB OR IV Non Small Cell Lung Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Achieve Life Sciences; OncoGenex Pharmaceuticals
  • Most Recent Events

    • 01 Aug 2017 According to Achieve Life Sciences media release, Achieve Life Sciences merged with OncoGenex Pharmaceuticals and the later changed its name to Achieve Life Sciences.
    • 01 Dec 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top